Charles River Laboratories International, Inc. (NYSE:CRL) Stock Position Decreased by SG Americas Securities LLC

SG Americas Securities LLC trimmed its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 93.1% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,198 shares of the medical research company’s stock after selling 29,506 shares during the period. SG Americas Securities LLC’s holdings in Charles River Laboratories International were worth $433,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Tortoise Investment Management LLC increased its position in Charles River Laboratories International by 77.0% in the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock worth $27,000 after buying an additional 57 shares during the period. Headlands Technologies LLC bought a new stake in shares of Charles River Laboratories International during the first quarter worth $41,000. Whittier Trust Co. of Nevada Inc. raised its position in shares of Charles River Laboratories International by 219.3% during the second quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company’s stock worth $58,000 after acquiring an additional 193 shares during the last quarter. Concord Wealth Partners raised its position in shares of Charles River Laboratories International by 362.5% during the first quarter. Concord Wealth Partners now owns 259 shares of the medical research company’s stock worth $70,000 after acquiring an additional 203 shares during the last quarter. Finally, Sunbelt Securities Inc. increased its holdings in Charles River Laboratories International by 1,072.7% in the first quarter. Sunbelt Securities Inc. now owns 258 shares of the medical research company’s stock valued at $70,000 after purchasing an additional 236 shares during the last quarter. 98.91% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. JPMorgan Chase & Co. cut Charles River Laboratories International from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $270.00 to $205.00 in a research note on Thursday, August 8th. Redburn Atlantic started coverage on Charles River Laboratories International in a research report on Monday. They set a “sell” rating and a $151.00 price target for the company. StockNews.com raised Charles River Laboratories International from a “hold” rating to a “buy” rating in a research report on Wednesday. Citigroup cut Charles River Laboratories International from a “neutral” rating to a “sell” rating and dropped their price target for the stock from $215.00 to $175.00 in a report on Tuesday, October 1st. Finally, TD Cowen dropped their price target on Charles River Laboratories International from $228.00 to $203.00 and set a “hold” rating for the company in a report on Monday, August 12th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $212.23.

Charles River Laboratories International Trading Up 1.3 %

Shares of CRL opened at $197.69 on Friday. Charles River Laboratories International, Inc. has a 52-week low of $161.65 and a 52-week high of $275.00. The business’s fifty day moving average is $197.26 and its 200-day moving average is $214.56. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.21 and a current ratio of 1.58. The firm has a market cap of $10.18 billion, a price-to-earnings ratio of 23.26, a PEG ratio of 5.11 and a beta of 1.36.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, August 7th. The medical research company reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $2.39 by $0.41. The business had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.03 billion. Charles River Laboratories International had a return on equity of 14.96% and a net margin of 10.83%. Equities analysts anticipate that Charles River Laboratories International, Inc. will post 10.01 EPS for the current fiscal year.

Charles River Laboratories International announced that its board has approved a share repurchase plan on Wednesday, August 7th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to buy up to 9.6% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its stock is undervalued.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).